Protara Therapeutics Announces Appointment of Martín Sebastian Olivo, M.D. as Chief Medical Officer
April 19 2021 - 8:00AM
Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage
company developing transformative therapies for the treatment of
cancer and rare diseases with significant unmet needs, today
announced the appointment of Martín Sebastian Olivo, M.D. as Chief
Medical Officer, effective immediately. Dr. Olivo brings to Protara
more than 15 years of experience in oncology translational and
clinical research and global drug development, most recently
serving as Vice President, Breast Cancer Clinical Development Lead
at Gilead Sciences, Inc. (formerly Immunomedics, Inc.).
“We are very excited to welcome Dr. Olivo to our
leadership team,” said Jesse Shefferman, Chief Executive Officer
of Protara Therapeutics. “The depth of his experience
supporting the development and approval of oncology drug candidates
is expected to be particularly instrumental as we continue to
advance our lead product candidate, TARA-002, for the treatment of
non-muscle invasive bladder cancer (NMIBC) and lymphatic
malformations.”
“TARA-002 has strong potential to play a
meaningful role in the treatment of NMIBC and potentially other
cancers,” said Dr. Olivo. “I look forward to working with this
dynamic leadership team to advance transformative therapies for
people with cancer and rare diseases of high unmet need.”
Prior to joining Protara, Dr. Olivo served as
Vice President, Breast Cancer Clinical Development Lead, at Gilead
Sciences, Inc. (formerly Immunomedics, Inc.), a public
biopharmaceutical company, from August 2018 to April 2021, where he
led clinical development of a treatment for metastatic
triple-negative breast cancer. Prior to joining Immunomedics, he
served as Global Clinical Lead at Daiichi Sankyo Cancer Enterprise,
a global pharmaceutical company, from July 2017 to July 2018, where
he established a comprehensive clinical development plan for an
early-stage oncology product candidate with applications in lung
and breast cancer. From January 2011 to July 2017, Dr. Olivo served
in several roles of increasing responsibility in the oncology
business group at Eisai Inc., a pharmaceutical company, most
recently serving as an International Project Team Leader.
Dr. Olivo received his M.D. from the University
of Buenos Aires and his M.S. in Clinical and Pharmacological
Research from Austral University in Buenos Aires. He completed his
degree as a Clinical Oncologist at the University of Salvador. He
has held various academic and clinical positions at the School of
Medicine at the University of Buenos Aires, Hospital “Dr. Enrique
Tornú” and the National Cancer Institute of Canada Clinical Trials
Group.
About Protara Therapeutics, Inc.
Protara is committed to identifying and
advancing transformative therapies for people with cancer and rare
diseases with limited treatment options. Protara’s portfolio
includes its lead program, TARA-002, an investigational cell-based
therapy being developed for the treatment of non-muscle invasive
bladder cancer and lymphatic malformations, and IV Choline
Chloride, an investigational phospholipid substrate replacement
therapy for the treatment of intestinal failure-associated liver
disease. For more information, visit www.protaratx.com.
Forward-Looking Statements
Statements contained in this press release
regarding matters that are not historical facts are "forward
looking statements" within the meaning of the Private Securities
Litigation Reform Act of 1995. Protara may, in some cases, use
terms such as “predicts,” “believes,” “potential,” “proposed,”
“continue,” “designed,” “estimates,” “anticipates,” “expects,”
“plans,” “intends,” “may,” “could,” “might,” “will,” “should” or
other words or expressions referencing future events, conditions or
circumstances that convey uncertainty of future events or outcomes
to identify these forward-looking statements. Such forward-looking
statements include but are not limited to, statements regarding
Protara’s intentions, beliefs, projections, outlook, analyses or
current expectations concerning, among other things: statements
regarding Protara’s business strategy, Protara’s development plans
for its product candidates and expectations regarding the
contribution of Dr. Olivo’s experience in helping Protara achieve
its strategic objectives. Because such statements are subject to
risks and uncertainties, actual results may differ materially from
those expressed or implied by such forward-looking statements.
Factors that contribute to the uncertain nature of the
forward-looking statements include risks and uncertainties
associated with: Protara’s development programs, including the
initiation and completion of non-clinical studies and clinical
trials and the timing of required filings with the FDA and other
regulatory agencies; the impact of the COVID-19 pandemic on
Protara’s business and the global economy; general market
conditions; changes in the competitive landscape; changes in
Protara’s strategic and commercial plans; Protara’s ability to
obtain sufficient financing to fund its strategic plans and
commercialization efforts; the loss of key members of management;
and the risks and uncertainties associated with Protara’s business
and financial condition in general, including the risks and
uncertainties described more fully under the caption "Risk Factors"
and elsewhere in Protara's filings and reports with the United
States Securities and Exchange Commission. All forward-looking
statements contained in this press release speak only as of the
date on which they were made and are based on management's
assumptions and estimates as of such date. Protara undertakes no
obligation to update any forward-looking statements, whether as a
result of the receipt of new information, the occurrence of future
events or otherwise, except as required by law.
Company Contact:
Justine O'MalleyProtara
TherapeuticsJustine.OMalley@protaratx.com646-817-2836
Protara Therapeutics (NASDAQ:TARA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Protara Therapeutics (NASDAQ:TARA)
Historical Stock Chart
From Jul 2023 to Jul 2024